eledon-logo-1230.png
Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
August 04, 2022 16:05 ET | Eledon Pharmaceuticals, Inc.
Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Second Quarter 2022 Financial Results
August 04, 2022 07:00 ET | Travere Therapeutics, Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update. New Drug Application...
eledon-logo-1230.png
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
August 01, 2022 05:00 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
eledon-logo-1230.png
Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
July 18, 2022 08:00 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Angion_2IN-02.jpg
Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease
June 29, 2022 16:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., June 29, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
eledon-logo-1230.png
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2022 16:05 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
eledon-logo-1230.png
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
June 09, 2022 08:00 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
eledon-logo-1230.png
Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2022 16:05 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
eledon-logo-1230.png
Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
May 12, 2022 16:01 ET | Eledon Pharmaceuticals, Inc.
Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022 First patient dosed in Phase 2a trial evaluating tegoprubart in IgA Nephropathy with...
eledon-logo-1230.png
Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
May 09, 2022 08:00 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...